OLMA · Olema Pharmaceuticals, Inc.
$8.23
-0.05 (-0.54%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“In addition, our condensed consolidated financial statements for the six months ended June 30, 2026 and 2025 included elsewhere in this Quarterly Report have been prepared assuming we will continue as a going concern. However, we have incurred losses and negative cash flows from operations. As a development stage company, we expect to incur significant and increasing losses until regulatory approval is granted for palazestrant or OP-3136. Regulatory approval is not guaranteed and may never be obtained. As a result, these conditions raise substantial doubt about our ability to continue as a going concern over the long term.”View the 10-Q filed Aug 10, 2026
Market Cap
$765.60M
Shares
87.50M
Volume · Oct 2
1.07M
Avg daily vol (3M)
1.09M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$8.23
Open$8.39
Day$8.10–8.52
52W close$7.77–35.83
Avg vol 30d1.1M
Short int16.1M · 18.4% float · 15.9d
Short vol80%
Last earningsMay 26, 2026
DataNov 2020–Oct 2026
Filing10-Q · Aug 10
Up next
Next earnings call
Jun 4, 2027
Est · unconfirmed
· in 35 wks
filed Aug 10, 2026
call held Mar 18, 2025
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$204.57M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$461.07M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+22.2%
Year over year · more shares
Price change (1Y)
-26.2%
Trailing year
Short interest
18.4%
Latest settlement · 15.9 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−49%
below
Price vs 50-day avg
−21%
below
RSI (14)
27
oversold
MACD trend
Negative
52-week position
2%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−23%
trailing
6-month return
−48%
trailing
YTD return
−67%
this year
Relative strength
−61%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $10 › 200d $16 — 200d above 50d
Institutional flow
Distributing
1 of 186 funds reported for Sep 30 · net -76 sh shares
Insider flow
Distributing
Net -$291.2K over 90 days · 100% sells
Short interest
Rising
18.36% of float · ▲ +2.6% MoM · 15.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
186 holders — mid 3-yr range
Squeeze score
69
elevated · 0–100
Fundamentals
EPS growth
+15%
Y/Y
Free cash flow
$-146.9M
Quant / Vol
risk profile
Volatility
154%
annualized · 1-yr
Max drawdown
−77%
past year
ATR
6.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−49%
Bearish
Price vs 50-day avg
−21%
Bearish
RSI (14)
27
Neutral
MACD trend
Negative
Bearish
52-week position
2%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $10 › 200d $16 — 200d above 50d
Institutional flow
Distributing
1 of 186 funds reported for Sep 30 · net -76 sh shares
Insider flow
Distributing
Net -$291.2K over 90 days · 100% sells
Short interest
Rising
18.36% of float · ▲ +2.6% MoM · 15.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
186 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $8
Now $8 · 2%
Range high $36
vs 200-day avg -49%
vs 50-day avg -21%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Non-GAAP general and administrative non-GAAP | 5.4M | Three Months Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP GAAP general and administrative 9.39M
-4.01M stock-based compensation expense
= Non-GAAP general and administrative 5.38M
|
|||
| Non-GAAP research and development non-GAAP | 48.9M | Three Months Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP GAAP research and development 57.79M
-8.89M stock-based compensation expense
= Non-GAAP research and development 48.89M
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OLMA
this stock
Olema Pharmaceuticals, Inc.
|
$765.60M | -67.1% | — | — | 18.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OLMA | -6.0% | -23.4% | -48.4% | -4.8% | -67.1% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -5.8% | -22.9% | -60.6% | -5.7% | -80.0% |